Cargando…

Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity

Numerous studies have shown a paradoxical positive correlation between elevated levels of plasminogen activator inhibitior-1 (PAI-1) in tumors and blood of cancer patients with poor clinical outcome, suggesting that PAI-1 could be a therapeutic target. Here we tested two orally bioavailable small mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Placencio, Veronica R., Ichimura, Atsuhiko, Miyata, Toshio, DeClerck, Yves A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514594/ https://www.ncbi.nlm.nih.gov/pubmed/26207899 http://dx.doi.org/10.1371/journal.pone.0133786

Ejemplares similares

Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis
por: Pelisch, Nicolas, et al.
Publicado: (2015)

Anti-Angiogenic Activity of a Small Molecule STAT3 Inhibitor LLL12
por: Bid, Hemant K., et al.
Publicado: (2012)

High efficacy and minimal peptide required for the anti-angiogenic and anti-hepatocarcinoma activities of plasminogen K5
por: Yang, Xia, et al.
Publicado: (2010)

Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model
por: Jeong, Bo Yeong, et al.
Publicado: (2016)

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis
por: Kwaan, H C, et al.
Publicado: (2000)

Phosphatase inhibitors with anti-angiogenic effect in vitro
por: SYLVEST, LENE, et al.
Publicado: (2010)

A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
por: Sillen, Machteld, et al.
Publicado: (2021)

Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
por: Chatterjee, Subhojyoti, et al.
Publicado: (2012)

Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis
por: Li, Tao, et al.
Publicado: (2016)

Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
por: Imai, Jin, et al.
Publicado: (2020)

Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
por: Yahata, Takashi, et al.
Publicado: (2020)

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
por: Henkel, Anne S., et al.
Publicado: (2018)

Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity
por: Kimani, Stanley G., et al.
Publicado: (2017)

Enhancing the anti-angiogenic action of histone deacetylase inhibitors
por: Kuljaca, Selena, et al.
Publicado: (2007)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease
por: Lee, Seon Myeong, et al.
Publicado: (2017)

Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities
por: Angulo, Javier, et al.
Publicado: (2015)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
por: Takahashi, Naoto, et al.
Publicado: (2022)

Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
Publicado: (2018)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
por: Faes, Seraina, et al.
Publicado: (2017)

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors
por: Singleton, Patrick A, et al.
Publicado: (2010)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis
por: Ansar, Syed Anas, et al.
Publicado: (2023)

Functional Stability of Plasminogen Activator Inhibitor-1
por: Yasar Yildiz, Songul, et al.
Publicado: (2014)

Activators and inhibitors of the plasminogen system in Alzheimer’s disease
por: Barker, Rachel, et al.
Publicado: (2012)

Anti-Angiogenic and Anti-Metastatic Activity of Synthetic Phosphoethanolamine
por: Ferreira, Adilson Kleber, et al.
Publicado: (2013)

The Anti-Angiogenic and Anti-Proliferative Activity of Methyl Hydroxychalcone
por: Sahib, Hayder B
Publicado: (2022)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
por: Tsai, Shih-Jen
Publicado: (2017)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Zuo, Yu, et al.
Publicado: (2021)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Ohuchi, Kentaro, et al.
Publicado: (2021)

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk
por: Demers-Mathieu, Veronique, et al.
Publicado: (2022)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_tcqca574f5idt80ot1pj4kspc6